Andrei H Iagaru, MD
Nuclear Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 6
Offices
6 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Iagaru’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A92375 · Current
Licensed to practise in California · since 2005 · expires 2027-08-31 · University of Medicine and Pharmacy 'Carol Davila'.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$49,562
Medicare paid this office $49,562 for 898 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 150 | $15,103 | $99 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 55 | $5,350 | $96 |
| Nuclear medicine study whole body with ct scan | 45 | $4,864 | $99 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 65 | $4,116 | $63 |
| Dxa bone density measurement of hip, pelvis, spine | 238 | $2,512 | $11 |
See all 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 150 | $15,103 | $99 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 55 | $5,350 | $96 |
| Nuclear medicine study whole body with ct scan | 45 | $4,864 | $99 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 65 | $4,116 | $63 |
| Dxa bone density measurement of hip, pelvis, spine | 238 | $2,512 | $11 |
| Nuclear medicine study whole body with ct scan | 24 | $2,432 | $101 |
| Dxa bone density measurement of hip, pelvis, spine | 146 | $1,532 | $10 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 21 | $1,185 | $56 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 14 | $624 | $45 |
| Nuclear medicine study of stomach to assess emptying | 19 | $624 | $33 |
| Nuclear medicine study of lymphatic system | 12 | $586 | $49 |
| Nuclear medicine study of bone and/or joint whole body | 14 | $483 | $34 |
| Nuclear medicine study of stomach to assess emptying | 11 | $357 | $32 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 14 | $0 | $0 |
Who their Medicare patients are
898 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 12% · Women 66% · Also on Medicaid 21% · Health risk score 1.85. At or below the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 68% · Cancer 37% · Diabetes 28% · Coronary heart disease 28% · Chronic kidney disease 28% · Depression 22% · Atrial fibrillation 20% · Heart failure 17% · COPD 13% · Stroke 10% · Dementia 9%.
The office billed $1,648,659, Medicare allowed $62,349 and paid $49,562; for 967 services of 43 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 898 | 967 | 74 | 1.85 | $1,648,659 | $49,562 |
| 2023 | 1,119 | 1,271 | 74 | 1.77 | $1,447,507 | $67,805 |
| 2022 | 1,074 | 1,193 | 75 | 1.78 | $849,565 | $66,727 |
| 2021 | 687 | 747 | 74 | 1.68 | $460,107 | $37,899 |
| 2020 | 859 | 948 | 73 | 1.89 | $562,368 | $56,612 |
| 2019 | 1,076 | 1,143 | 73 | 1.87 | $456,829 | $69,138 |
| 2018 | 1,961 | 2,182 | 73 | 1.84 | $712,748 | $112,478 |
| 2017 | 1,608 | 1,770 | 72 | 1.74 | $598,152 | $99,725 |
| 2016 | 1,071 | 1,200 | 72 | 2.01 | $457,222 | $76,944 |
| 2015 | 1,038 | 1,173 | 72 | 1.85 | $415,096 | $71,125 |
| 2014 | 972 | 1,104 | 71 | 1.82 | $370,531 | $63,247 |
| 2013 | 967 | 1,104 | 71 | 1.75 | $361,557 | $57,691 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 183 | $19,532 | $103 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 76 | $8,094 | $105 |
| Nuclear medicine study whole body with ct scan | 73 | $7,920 | $106 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 88 | $5,998 | $68 |
| Dxa bone density measurement of hip, pelvis, spine | 407 | $4,439 | $11 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 66 | $4,207 | $62 |
| Nuclear medicine study whole body with ct scan | 32 | $3,522 | $104 |
| Radioactive drug therapy through a vein | 25 | $2,465 | $88 |
| Nuclear medicine study of bone and/or joint whole body | 31 | $1,187 | $36 |
| Calculation of radiation therapy dose | 29 | $968 | $31 |
| Nuclear medicine study of lymphatic system | 16 | $820 | $51 |
| Dxa bone density measurement of hip, pelvis, spine | 62 | $668 | $11 |
| Nuclear medicine study of stomach to assess emptying | 17 | $583 | $34 |
2022: 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 230 | $23,307 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 84 | $8,752 | $101 |
| Nuclear medicine study whole body with ct scan | 76 | $7,806 | $101 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 98 | $6,018 | $61 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 63 | $3,841 | $59 |
| Dxa bone density measurement of hip, pelvis, spine | 310 | $3,412 | $11 |
| Nuclear medicine study whole body with ct scan | 31 | $3,153 | $102 |
| Nuclear medicine study of bone and/or joint whole body | 28 | $1,024 | $35 |
| Dxa bone density measurement of hip, pelvis, spine | 69 | $748 | $11 |
| Nuclear medicine study of stomach to assess emptying | 24 | $727 | $30 |
| Nuclear medicine study of lung ventilation and circulation | 13 | $609 | $47 |
| Nuclear medicine study of lymphatic system | 11 | $573 | $52 |
| Nuclear medicine study, 1 area | 15 | $426 | $28 |
| Calculation of radiation therapy dose | 13 | $390 | $30 |
2021: 8 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 144 | $14,022 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 58 | $4,043 | $70 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 53 | $3,415 | $63 |
| Nuclear medicine study whole body with ct scan | 34 | $3,121 | $89 |
| Dxa bone density measurement of hip, pelvis, spine | 234 | $2,621 | $11 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 20 | $2,164 | $108 |
| Nuclear medicine study of bone and/or joint whole body | 32 | $1,110 | $34 |
| Dxa bone density measurement of hip, pelvis, spine | 44 | $486 | $11 |
2020: 12 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 157 | $17,897 | $108 |
| Nuclear medicine study whole body with ct scan | 65 | $7,827 | $112 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 65 | $7,051 | $107 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 80 | $5,519 | $69 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 57 | $3,741 | $66 |
| Dxa bone density measurement of hip, pelvis, spine | 250 | $2,883 | $12 |
| Nuclear medicine study whole body with ct scan | 17 | $2,028 | $113 |
| Nuclear medicine study of bone and/or joint whole body | 36 | $1,443 | $38 |
| Nuclear medicine study of lymphatic system | 20 | $1,033 | $52 |
| Dxa bone density measurement of hip, pelvis, spine | 41 | $468 | $11 |
| Nuclear medicine study of lung circulation | 13 | $410 | $32 |
| Nuclear medicine study of stomach to assess emptying | 13 | $402 | $31 |
2019: 11 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 219 | $24,637 | $106 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 100 | $11,179 | $107 |
| Nuclear medicine study whole body with ct scan | 79 | $9,124 | $109 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 109 | $7,621 | $69 |
| Dxa bone density measurement of hip, pelvis, spine | 297 | $3,338 | $11 |
| Nuclear medicine study whole body with ct scan | 21 | $2,310 | $110 |
| Nuclear medicine study of bone and/or joint whole body | 48 | $1,806 | $36 |
| Nuclear medicine study of stomach to assess emptying | 24 | $816 | $34 |
| Nuclear medicine study of lung ventilation and circulation | 16 | $769 | $48 |
| Dxa bone density measurement of hip, pelvis, spine | 66 | $738 | $11 |
| Nuclear medicine study of lymphatic system | 11 | $588 | $53 |
2018: 24 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 347 | $38,119 | $100 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 133 | $13,423 | $97 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 193 | $12,955 | $67 |
| Nuclear medicine study whole body with ct scan | 93 | $11,417 | $104 |
| Dxa bone density measurement of hip, pelvis, spine | 626 | $7,237 | $12 |
| Nuclear medicine study whole body with ct scan | 43 | $4,663 | $97 |
| Nuclear medicine study of bone and/or joint whole body | 88 | $2,898 | $31 |
| Nuclear medicine study of lung ventilation and circulation | 42 | $1,943 | $46 |
| Nuclear medicine study of stomach to assess emptying | 56 | $1,780 | $31 |
| Nuclear medicine study of lymphatic system | 34 | $1,686 | $50 |
| Dxa bone density measurement of hip, pelvis, spine | 128 | $1,469 | $11 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $1,373 | $65 |
| Nuclear medicine study from skull base to mid-thigh | 17 | $954 | $56 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 21 | $946 | $43 |
| Nuclear medicine study of heart muscle with metabolic evaluation | 12 | $764 | $64 |
| Nuclear medicine study of bone taken at different times | 17 | $763 | $45 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 12 | $687 | $53 |
| Nuclear medicine study of heart muscle at rest and with stress and spect | 12 | $669 | $56 |
| Nuclear medicine study of lymphatic system | 13 | $633 | $49 |
| Nuclear medicine study of bone and/or joint | 13 | $544 | $42 |
| Nuclear medicine study, whole body | 14 | $473 | $34 |
| Nuclear medicine study of radioactive material distribution at sites of inflammation in whole body | 14 | $452 | $32 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 11 | $402 | $37 |
| Nuclear medicine study of liver | 13 | $331 | $25 |
2017: 12 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 449 | $51,236 | $102 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 117 | $13,491 | $107 |
| Nuclear medicine study whole body with ct scan | 105 | $11,546 | $104 |
| Dxa bone density measurement of hip, pelvis, spine | 698 | $8,077 | $12 |
| Nuclear medicine study whole body with ct scan | 29 | $3,485 | $109 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $2,287 | $64 |
| Nuclear medicine study of bone and/or joint whole body | 47 | $1,618 | $32 |
| Nuclear medicine study of lymphatic system | 17 | $796 | $47 |
| Nuclear medicine study of heart muscle with metabolic evaluation | 14 | $753 | $54 |
| Nuclear medicine study of stomach to assess emptying | 22 | $645 | $29 |
| Nuclear medicine study of lung ventilation and circulation | 15 | $574 | $38 |
| Dxa bone density measurement of hip, pelvis, spine | 49 | $554 | $11 |
2016: 9 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 457 | $50,578 | $103 |
| Nuclear medicine study whole body with ct scan | 63 | $7,074 | $103 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 53 | $3,768 | $71 |
| Dxa bone density measurement of hip, pelvis, spine | 307 | $3,543 | $12 |
| Nuclear medicine study of bone and/or joint whole body | 54 | $1,910 | $34 |
| Nuclear medicine study of lymphatic system | 28 | $1,377 | $49 |
| Nuclear medicine study of stomach to assess emptying | 32 | $958 | $30 |
| Nuclear medicine study of lung ventilation and circulation | 19 | $900 | $47 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 18 | $841 | $47 |
2015: 12 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 392 | $45,515 | $105 |
| Nuclear medicine study whole body with ct scan | 45 | $5,107 | $106 |
| Dxa bone density measurement of hip, pelvis, spine | 315 | $3,643 | $12 |
| Nuclear medicine study of bone and/or joint whole body | 80 | $2,880 | $35 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 42 | $2,786 | $66 |
| Nuclear medicine study of lymphatic system | 28 | $1,445 | $52 |
| Nuclear medicine study of lung ventilation and circulation | 23 | $1,001 | $44 |
| Nuclear medicine study of stomach to assess emptying | 22 | $782 | $33 |
| Nuclear medicine study of bone and/or joint | 14 | $634 | $45 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 12 | $548 | $46 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 11 | $441 | $40 |
| Nuclear medicine study of liver | 13 | $395 | $30 |
2014: 16 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 360 | $41,261 | $105 |
| Nuclear medicine study of bone and/or joint whole body | 93 | $3,418 | $35 |
| Dxa bone density measurement of hip, pelvis, spine | 283 | $3,263 | $12 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $2,202 | $61 |
| Nuclear medicine study of lung ventilation and circulation | 35 | $1,650 | $46 |
| Nuclear medicine study whole body with ct scan | 15 | $1,411 | $94 |
| Nuclear medicine study of lymphatic system | 25 | $1,260 | $50 |
| Nuclear medicine study of stomach to assess emptying | 30 | $1,133 | $35 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 21 | $971 | $46 |
| Nuclear medicine study of bone and/or joint | 14 | $605 | $43 |
| Supervision, handling, and loading of radiation source | 11 | $527 | $48 |
| Nuclear medicine study of bone taken at different times | 11 | $493 | $45 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 11 | $440 | $40 |
| Nuclear medicine study of liver | 13 | $365 | $28 |
| Nuclear medicine study of kidney and blood flow | 15 | $347 | $22 |
| Calculation of radiation therapy dose | 11 | $315 | $29 |
2013: 13 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 346 | $36,318 | $95 |
| Dxa bone density measurement of hip, pelvis, spine | 297 | $3,252 | $11 |
| Nuclear medicine study of bone and/or joint whole body | 87 | $3,009 | $33 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $2,234 | $62 |
| Nuclear medicine study whole body with ct scan | 19 | $1,763 | $88 |
| Nuclear medicine study of lung ventilation and circulation | 32 | $1,456 | $45 |
| Nuclear medicine study of stomach to assess emptying | 29 | $1,165 | $33 |
| Nuclear medicine study of lymphatic system | 21 | $1,026 | $49 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 20 | $746 | $36 |
| Supervision, handling, and loading of radiation source | 12 | $550 | $46 |
| Nuclear medicine study of bone and/or joint | 11 | $475 | $40 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 11 | $434 | $39 |
| Calculation of radiation therapy dose | 12 | $327 | $27 |
Medicaid work
$23,560 in 2024
Medicaid paid $23,560 for 114 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 88 | $23,248 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 26 | $312 |
| 2024 | 114 | 2 | 33 | $23,560 |
| 2023 | 122 | 2 | 24 | $16,639 |
| 2022 | 115 | 2 | 26 | $10,249 |
| 2021 | 27 | 1 | 14 | $144 |
| 2020 | 70 | 2 | 16 | $7,876 |
| 2019 | 56 | 1 | 25 | $11,869 |
| 2018 | 249 | 3 | 30 | $32,403 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 96 | $16,517 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 26 | $122 |
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 67 | $10,040 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 48 | $209 |
2021
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 27 | $144 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 44 | $7,756 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 26 | $119 |
2019
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 56 | $11,869 |
2018
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 159 | $31,440 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 78 | $609 |
| Gastric emptying imaging study (eg, solid, liquid, or both) | 12 | $354 |
Money from drug and device companies
$44,138 in 2025
| 2025 | 5 | 17 | $25,545 | $44,138 |
| 2024 | 5 | 16 | $1,400 | $18,222 |
| 2023 | 3 | 23 | $9,063 | $21,905 |
| 2022 | 3 | 12 | $7,012 | $29,079 |
| 2021 | 3 | 6 | $10,000 | $10,229 |
| 2020 | 3 | 7 | $4,575 | $11,665 |
| 2019 | 1 | 30 | None | $15,177 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lantheus Medical Imaging | None | $27,136 | 4 payments
|
| Ge Healthcare | None | $10,782 | 6 payments
|
| Genzyme | None | $3,197 | 3 payments
|
| Novartis Pharmaceuticals | None | $2,810 | 3 payments
|
| Progenics Pharmaceuticals | Pylarify | $214 | 1 payment
|
See all 17 published payments
| Lantheus Medical Imaging | Consulting · 2025-11-25 | None | $7,950 |
| Lantheus Medical Imaging | Consulting · 2025-11-18 | None | $3,975 |
| Lantheus Medical Imaging | Travel · 2025-11-18 | None | $7,261 |
| Lantheus Medical Imaging | Consulting · 2025-11-06 | None | $7,950 |
| Progenics Pharmaceuticals | Meals · 2025-09-11 | Pylarify | $214 |
| Ge Healthcare | Meals · 2025-08-24 | None | $96 |
| Ge Healthcare | Meals · 2025-08-22 | None | $100 |
| Ge Healthcare | Travel · 2025-08-22 | None | $9,540 |
| Ge Healthcare | Travel · 2025-08-22 | None | $682 |
| Ge Healthcare | Travel · 2025-06-24 | None | $239 |
| Novartis Pharmaceuticals | Meals · 2025-06-20 | None | $34 |
| Ge Healthcare | Meals · 2025-06-20 | None | $124 |
| Novartis Pharmaceuticals | Meals · 2025-02-14 | None | $76 |
| Novartis Pharmaceuticals | Consulting · 2025-02-14 | None | $2,700 |
| Genzyme | Consulting · 2025-01-22 | None | $2,970 |
| Genzyme | Travel · 2025-01-22 | None | $112 |
| Genzyme | Meals · 2025-01-22 | None | $115 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $18,222
| Ge Healthcare | None | $16,203 | 10 payments
|
| Eli Lilly and | None | $1,454 | 2 payments
|
| Telix Pharmaceuticals | Illuccix | $308 | 2 payments
|
| Novartis Pharmaceuticals | Pluvicto | $216 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $42 | 1 payment
|
2023: $21,905
| Novartis Pharmaceuticals | Pluvicto | $11,049 | 11 payments
|
| GE HealthCare | None | $10,832 | 11 payments
|
| Progenics Pharmaceuticals | Pylarify | $23 | 1 payment
|
2022: $29,079
| GE HealthCare | None | $22,067 | 10 payments
|
| Progenics Pharmaceuticals | Pylarify | $4,500 | 1 payment
|
| Amgen | None | $2,512 | 1 payment
|
2021: $10,229
| Novartis Pharmaceuticals | Lutathera | $7,116 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $3,000 | 1 payment
|
| Ge Healthcare | None | $113 | 3 payments
|
2020: $11,665
| GE Healthcare | None | $7,090 | 5 payments
|
| Progenics Pharmaceuticals | None | $2,700 | 1 payment
|
| Advanced Accelerator Applications | Lutathera | $1,875 | 1 payment
|
2019: $15,177
| Ge Healthcare | None | $15,177 | 30 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| GE HEALTHCARE · Pard Projects · 2019 | Their institution | $749,837 |
| GE HEALTHCARE · Mri Technology Development/Evaluation · 2023 | Their institution | $603,180 |
| GE HEALTHCARE · Advanced Research for Digital Petct · 2020 | Their institution | $444,540 |
| Novartis Pharmaceuticals Corporation · An Open-Label, Randomized, Phase III Study Comparing 177lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2023 | Their institution | $363,542 |
| GE HEALTHCARE · Digital Pet/Ct Evaluations · 2019 | Their institution | $326,062 |
| GE HEALTHCARE · Pet/Mri Advanced Research and Development - Neuro · 2022 | Their institution | $307,591 |
| GE Healthcare · Advanced Pet Application Testing · 2021 | Their institution | $301,591 |
| Novartis Pharmaceuticals Corporation · (Ma-Psmar2-1-2) 68ga-Neobomb1 and 68ga-Psma R2 Pet/Mri in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer · 2024 | Their institution | $249,360 |
| Novartis Pharmaceuticals Corporation · An Open-Label, Randomized, Phase III Study Comparing 177lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2024 | Their institution | $174,294 |
| Progenics Pharmaceuticals, Inc. · Study of 18f Dcfpyl Pet Ct Imaging in Patients With Suspected Recurrence of Prostate Cancer Condor · 2019 | Their institution | $37,684 |
| GE HEALTHCARE · Early Evaluation of Starguide Spect/Ct in Clinical Practice · 2022 | Their institution | $28,463 |
| AstraZeneca Pharmaceuticals LP · A Phase 1 First-in-Human Multicentre Open-Label Dose Escalation Study of 225ac-Fpi-2068 in Adult Patients With Advanced Solid Tumours · 2025 | Their institution | $27,725 |
| Progenics Pharmaceuticals, Inc. · Phase 3 Randomized Trial of Psma Pet Prior To Definitive Radiotherapy for Intermediate- Or High-Risk Prostate Cancer · 2021 | Their institution | $23,000 |
| Progenics Pharmaceuticals, Inc. · Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (Arrow) · 2020 | Their institution | $18,630 |
| Progenics Pharmaceuticals, Inc. · Impact of Pyl Pet/Ct on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer (Prospyl) · 2021 | Their institution | $18,400 |
| Advanced Accelerator Applications · Neoray · 2020 | Their institution | $17,984 |
| Novartis Pharmaceuticals Corporation · An Open-Label, Randomized, Phase III Study Comparing 177lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2022 | Their institution | $14,972 |
| GE HEALTHCARE · Early Evaluation of Starguide Spect/Ct in Clinical Practice · 2021 | Their institution | $14,232 |
| Progenics Pharmaceuticals, Inc. · 18f-Dcfpyl Pet/Ct in the Evaluation of Patients With Bcr of Prostate Cancer and Non-Contributory Ct Scans · 2021 | Their institution | $13,800 |
| Progenics Pharmaceuticals, Inc. · Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant · 2022 | Their institution | $11,840 |
| Progenics Pharmaceuticals, Inc. · A Phase II Multi-Institutional Trial To Evaluate Prostate Specific Membrane Antigen (Psma)-Based Pet Imaging of High Risk Prostate Cancer-Moonshot-Mskcc · 2021 | Their institution | $9,200 |
| GE HEALTHCARE · Stanford Pet-Mr · 2021 | Their institution | $6,000 |
| Progenics Pharmaceuticals, Inc. · 18f-Dcfpyl Pet/Ct in Men With Prostate Cancer · 2021 | Their institution | $4,600 |
| Progenics Pharmaceuticals, Inc. · The Utility of Psma-Pet Imaging for Detecting Early Metastatic Prostate Cancer in Men With High Gc Decipher Test Scores:A Sub-Aim of the Vandaam Study (Mcc #18523) · 2021 | Their institution | $4,600 |
| Progenics Pharmaceuticals, Inc. · Study of 18f Dcfpyl Pet Ct Imaging in Patients With Suspected Recurrence of Prostate Cancer Condor · 2020 | Their institution | $2,131 |
| PROGENICS PHARMACEUTICALS, INC. · Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castra · 2023 | Their institution | $1,280 |
| Novartis Pharma AG · Caaa617d12302 · 2025 | This clinician | $1,125 |
| Novartis Pharmaceuticals Corporation · Research Publication/Writing Support · 2025 | This clinician | $509 |
| Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177lu]Lu-Ff58 in Patients With Selected Advanced Solid Tumors · 2024 | Their institution | $505 |
| Progenics Pharmaceuticals, Inc. · Study of 18f Dcfpyl Pet Ct Imaging in Patients With Suspected Recurrence of Prostate Cancer Condor · 2020 | This clinician | $175 |
| Novartis Pharmaceuticals Corporation · An Open-Label, Randomized, Phase III Study Comparing 177lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2025 | Their institution | $115 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1750404752
- Licence
- CA A92375California A92375: Current · expires 2027-08-31
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2085N0904X (2085N0904X); Federal specialty code 207U00000X (207U00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-04-06
- NPI last updated
- 2024-04-09
- NPI record certified
- 2024-04-09
This is when the NPI record was last certified, not a medical board exam.